Opportunity Information: Apply for PAR 13 213
Apply for PAR 13 213
- The National Institutes of Health in the health income security and social services sector is offering a public funding opportunity titled "Outcome Measures for Use in Treatment Trials for Individuals with Intellectual and Developmental Disabilities (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.242 Mental Health Research Grants 93.865 Child Health and Human Development Extramural Research.
- This funding opportunity was created on Apr 25, 2013 and posted on Apr 25, 2013.
- Applicants must submit their applications by May 7, 2016. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: For profit organizations other than small businesses Public housing authorities/Indian housing authorities Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education City or township governments Public and State controlled institutions of higher education Native American tribal governments (Federally recognized) Private institutions of higher education Special district governments County governments Independent school districts Others (see text field entitled Additional Information on Eligibility for clarification) State governments Small businesses Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Asian American Native American Pacific Islander Serving Institutions (AANAPISISs) Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The NIH grant opportunity titled "Outcome Measures for Use in Treatment Trials for Individuals with Intellectual and Developmental Disabilities (R01)" (Funding Opportunity Number PAR-13-213) supports research projects that create and refine outcome measures specifically suited for clinical trials involving individuals with intellectual and developmental disabilities (IDD). The core purpose is to fix a major bottleneck in IDD treatment development: even when there are promising therapeutic ideas, including drug-based approaches, progress can stall because researchers lack reliable, sensitive, and clinically meaningful ways to measure change in these populations. The FOA is designed to push the field toward better tools for assessing whether an intervention truly improves functioning, symptoms, behavior, or other relevant domains for people with IDD, and to make those tools practical for use in clinical and translational research settings.
This is an R01 Research Project Grant, meaning it is intended for substantial, hypothesis-driven or measure-development work that can support a full research program rather than a small pilot. The scientific emphasis is on developing "informative" outcome measures, which generally implies measures that are valid (they measure what they claim to measure), reliable (they produce consistent results), sensitive to change (they can detect improvement or deterioration over time), and appropriate for the wide range of abilities, communication styles, and support needs seen across IDD populations. The announcement highlights that the need is especially pressing for pharmacological trials, where treatment effects may be subtle and where endpoints must be credible to the research community and, ultimately, to regulators and clinicians.
The FOA sits within the broader NIH mission areas tied to mental health and child health/development, as reflected in the CFDA program listings 93.242 (Mental Health Research Grants) and 93.865 (Child Health and Human Development Extramural Research). The activity category is listed under Health, Income Security, and Social Services, but the practical thrust is biomedical/clinical measurement development that improves the quality of treatment trials. While the text does not enumerate specific required measure types, the intent is to encourage outcomes that can be used in real-world trials with IDD participants, including endpoints that are meaningful to daily life and that can be implemented across studies to improve comparability and accelerate progress.
Eligibility is broad and includes a wide range of U.S. and non-U.S. organizations. Eligible applicants include public and private institutions of higher education, nonprofits with or without 501(c)(3) status, for-profit organizations (including small businesses, and for-profit entities other than small businesses), state and local governments (including counties, cities or townships, special districts, and independent school districts), public housing authorities/Indian housing authorities, federally recognized tribal governments, and other tribal organizations. The FOA also explicitly includes a variety of institution types such as HBCUs, Hispanic-serving institutions, AANAPISIs, Alaska Native and Native Hawaiian-serving institutions, and tribally controlled colleges and universities. Foreign organizations and foreign institutions are eligible to apply, non-U.S. components of U.S. organizations may participate, and foreign components are allowed consistent with NIH policy. There is no cost-sharing or matching requirement, which reduces barriers for applicants building measurement infrastructure or conducting multi-site validation work.
Administratively, the opportunity was posted and created on April 25, 2013, with the original and current closing date listed as May 7, 2016, and an archive date of June 7, 2016, indicating the FOA is no longer open but remains available as a reference point for the kind of work NIH was seeking. The sponsoring agency is the National Institutes of Health. The full announcement was hosted on the NIH grants website at the provided link (http://grants.nih.gov/grants/guide/pa-files/PAR-13-213.html). For technical issues accessing the announcement, NIH directed applicants to contact the NIH Office of Extramural Research (OER) webmaster.
Finally, the FOA points applicants to a related NIH opportunity focused on preclinical research in model organisms to predict treatment outcomes for IDD-associated disorders, signaling a broader pipeline perspective: better preclinical prediction paired with better clinical outcome measurement. Taken together, this grant announcement targets a practical but scientifically demanding gap in IDD research, aiming to produce measurement tools that make treatment trials more interpretable, more comparable across studies, and more likely to yield clear answers about what helps individuals with intellectual and developmental disabilities.
FAQs: Outcome Measures for Use in Treatment Trials for Individuals with Intellectual and Developmental Disabilities (R01) (PAR-13-213)
What is the title of this NIH grant opportunity?
The opportunity is titled "Outcome Measures for Use in Treatment Trials for Individuals with Intellectual and Developmental Disabilities (R01)."
What is the Funding Opportunity Number (FOA number)?
The Funding Opportunity Number is PAR-13-213.
What is the main purpose of this FOA?
The purpose is to support research projects that create and refine outcome measures specifically suited for clinical trials involving individuals with intellectual and developmental disabilities (IDD). The FOA is aimed at reducing a major bottleneck in IDD treatment development: promising interventions can stall when researchers do not have reliable, sensitive, and clinically meaningful ways to measure change in IDD populations.
What problem in IDD treatment development is this FOA trying to address?
It targets the lack of credible, practical outcome measures for treatment trials in IDD. Without strong endpoints, it can be difficult to determine whether an intervention truly improves functioning, symptoms, behavior, or other important domains for people with IDD.
What kind of grant mechanism is this?
This is an R01 Research Project Grant.
What does it mean that this is an R01?
In this FOA, the R01 format indicates support for substantial, hypothesis-driven or measure-development work that can sustain a full research program, rather than a small pilot effort.
What types of research does the FOA support?
The FOA supports research to develop and refine "informative" outcome measures for use in clinical trials and clinical/translational research involving individuals with IDD.
What does the FOA mean by "informative" outcome measures?
Based on the description, "informative" generally implies outcome measures that are valid (measure what they claim to measure), reliable (produce consistent results), sensitive to change (detect improvement or deterioration over time), and appropriate for the wide range of abilities, communication styles, and support needs seen across IDD populations.
Why does the FOA emphasize sensitivity to change?
Treatment effects in IDD trials, especially pharmacological trials, may be subtle. Measures that are sensitive to change are critical for detecting meaningful improvement or decline over time.
Is the FOA especially relevant to pharmacological (drug) trials?
Yes. The announcement highlights that the need is especially pressing for pharmacological trials, where endpoints must be credible to the research community and ultimately useful to regulators, clinicians, and other decision-makers.
Does the FOA require specific types of outcome measures?
No specific required measure types are listed in the provided information. The intent is to encourage outcomes that can be used in real-world trials with IDD participants, including endpoints meaningful to daily life and practical to implement across studies.
What is the practical goal for the measures developed under this FOA?
The measures are intended to make treatment trials more interpretable and more comparable across studies, helping the field reach clearer answers about what helps individuals with intellectual and developmental disabilities.
What NIH mission areas or program listings are associated with this FOA?
The FOA is tied to NIH mission areas reflected in CFDA program listings 93.242 (Mental Health Research Grants) and 93.865 (Child Health and Human Development Extramural Research).
Which agency sponsors this funding opportunity?
The sponsoring agency is the National Institutes of Health (NIH).
Who is eligible to apply?
Eligibility is broad. Eligible applicants include public and private institutions of higher education; nonprofits with or without 501(c)(3) status; for-profit organizations (including small businesses and other for-profit entities); state and local governments (including counties, cities or townships, special districts, and independent school districts); public housing authorities/Indian housing authorities; federally recognized tribal governments; and other tribal organizations.
Are minority-serving institutions explicitly included as eligible applicants?
Yes. The FOA explicitly includes institution types such as HBCUs, Hispanic-serving institutions, AANAPISIs, Alaska Native and Native Hawaiian-serving institutions, and tribally controlled colleges and universities.
Can foreign (non-U.S.) organizations apply?
Yes. Foreign organizations and foreign institutions are eligible to apply.
Can non-U.S. components of U.S. organizations participate?
Yes. Non-U.S. components of U.S. organizations may participate, and foreign components are allowed consistent with NIH policy.
Is cost-sharing or matching required?
No. The FOA states there is no cost-sharing or matching requirement.
When was this FOA posted?
The opportunity was posted (and created) on April 25, 2013.
What was the closing date for applications?
The original and current closing date listed is May 7, 2016.
Is this FOA still open for applications?
No. The archive date is June 7, 2016, indicating the FOA is no longer open and is retained as a reference.
Where can the full FOA be found?
The full announcement was hosted on the NIH grants website at: http://grants.nih.gov/grants/guide/pa-files/PAR-13-213.html
Who should be contacted for technical issues accessing the announcement?
For technical issues accessing the announcement, NIH directed applicants to contact the NIH Office of Extramural Research (OER) webmaster.
How does this FOA fit into a broader research pipeline?
The FOA points to a related NIH opportunity focused on preclinical research in model organisms to predict treatment outcomes for IDD-associated disorders. This signals a broader pipeline approach: improving preclinical prediction alongside improving clinical outcome measurement.
What is the overarching impact NIH was aiming for with this FOA?
The announcement targets a practical but scientifically demanding gap in IDD research: producing measurement tools that help trials yield clearer, more comparable, and more actionable evidence about whether interventions improve outcomes for individuals with IDD.
Browse more opportunities from the same category: Health Income Security and Social Services
Next opportunity: Preclinical Research on Model Organisms to Predict Treatment Outcomes for Disorders Associated with Intellectual and Developmental Disabilities (R01)
Previous opportunity: Tribal Wildlife Grants FY2014
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PAR 13 213
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PAR 13 213) also looked into and applied for these:
| Funding Opportunity |
|---|
| Preclinical Research on Model Organisms to Predict Treatment Outcomes for Disorders Associated with Intellectual and Developmental Disabilities (R01) Apply for PAR 13 195 Funding Number: PAR 13 195 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $499,999 |
| Pediatric Critical Care and Trauma Scientist Development Program (K12) Apply for RFA HD 14 019 Funding Number: RFA HD 14 019 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $720,037 |
| In vivo Methods for Assessing Placental Development and Function (SBIR) (R43/R44) Apply for RFA HD 14 005 Funding Number: RFA HD 14 005 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| In vivo Methods for Assessing Placental Development and Function (R41/R42) Apply for RFA HD 14 004 Funding Number: RFA HD 14 004 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| NICHD Program Project Grant (P01) Apply for PAR 13 257 Funding Number: PAR 13 257 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Paul D. Wellstone Muscular Dystrophy Cooperative Research Centers (U54) Apply for RFA AR 13 021 Funding Number: RFA AR 13 021 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Developmental Mechanisms of Human Structural Birth Defects (P01) Apply for PAR 13 285 Funding Number: PAR 13 285 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Biomarkers Bridging Pediatric and Adult Therapeutics (R03) Apply for PAR 13 299 Funding Number: PAR 13 299 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $50,000 |
| Biomarkers Bridging Pediatric and Adult Therapeutics (R21) Apply for PAR 13 295 Funding Number: PAR 13 295 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $200,000 |
| Biomarkers Bridging Pediatric and Adult Therapeutics (R01) Apply for PAR 13 296 Funding Number: PAR 13 296 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Translational Research in Pediatric and Obstetric Pharmacology and Therapeutics (R01) Apply for PAR 13 309 Funding Number: PAR 13 309 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Translational Research in Pediatric and Obstetric Pharmacology and Therapeutics (R03) Apply for PAR 13 310 Funding Number: PAR 13 310 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $50,000 |
| Translational Research in Pediatric and Obstetric Pharmacology and Therapeutics (R21) Apply for PAR 13 311 Funding Number: PAR 13 311 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $200,000 |
| Development of Appropriate Pediatric Formulations and Pediatric Drug Delivery Systems (R01) Apply for PAR 13 325 Funding Number: PAR 13 325 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Development of Appropriate Pediatric Formulations and Pediatric Drug Delivery Systems (R21) Apply for PAR 13 326 Funding Number: PAR 13 326 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $200,000 |
| Development of Appropriate Pediatric Formulations and Drug Delivery Systems (R03) Apply for PAR 13 344 Funding Number: PAR 13 344 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $50,000 |
| Development of Appropriate Pediatric Formulations and Drug Delivery Systems (R43) Apply for PAR 13 345 Funding Number: PAR 13 345 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $150,000 |
| Development of Appropriate Pediatric Formulations and Drug Delivery Systems STTR (R41) Apply for PAR 13 346 Funding Number: PAR 13 346 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Sustained Release of Antivirals for Treatment and Prevention of HIV (SRATP) (R01) Apply for PAR 13 349 Funding Number: PAR 13 349 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: Case Dependent |
| Enhancing the Capacity for Biomedical Research on Tuberculosis for HIV infected Mothers and Children in India (R01) Apply for RFA HD 14 025 Funding Number: RFA HD 14 025 Agency: National Institutes of Health Category: Health Income Security and Social Services Funding Amount: $350,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PAR 13 213", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.